Sugi Predict

Sugi Predict / Compounds / SCHEMBL7187030

SCHEMBL7187030

SCHEMBL7187030

CCOc1ccc(PC(=O)c2c(OC)cccc2OC)c(OCC)c1.[LiH]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ ALDH1A1 P00352 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPT P10636 5/20 0.43
▸ TSHR P16473 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MAPK1 P28482 2/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ HIF1A Q16665 1/20 0.40
▸ KCNK3 O14649 1/20 0.40
▸ KCNK9 Q9NPC2 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7187037 0.97 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1KDM4EMAPTTSHR
SCHEMBL7189259 0.93 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1KDM4EMAPTTSHR
SCHEMBL7180673 0.91 KDM4E (0.45) SMN1; SMN2KDM4EMAPTTSHRLMNA
Lithium SCHEMBL7189263 0.91 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1KDM4EMAPTTSHR
SCHEMBL7187068 0.89 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1KDM4EMAPTTSHR
Lithium SCHEMBL7180686 0.89 KDM4E (0.45) SMN1; SMN2KDM4EMAPTTSHRLMNA
SCHEMBL7174883 0.88 THRB (0.42) SMN1; SMN2MAPTLMNACA12CA1
SCHEMBL7180946 0.88 KMT2A (0.42) SMN1; SMN2MAPTLMNACA12CA1
SCHEMBL7187392 0.87 MAPT (0.46) SMN1; SMN2ALDH1A1KDM4EMAPTLMNA
SCHEMBL7181649 0.86 MAPT (0.44) SMN1; SMN2ALDH1A1KDM4EMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885ALDH1A1 3416/4885KDM4E 3226/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885ALDH1A1 3984/4885KDM4E 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.